BR112014022562A8 - Formulação de rna para imunoterapia - Google Patents
Formulação de rna para imunoterapiaInfo
- Publication number
- BR112014022562A8 BR112014022562A8 BR112014022562A BR112014022562A BR112014022562A8 BR 112014022562 A8 BR112014022562 A8 BR 112014022562A8 BR 112014022562 A BR112014022562 A BR 112014022562A BR 112014022562 A BR112014022562 A BR 112014022562A BR 112014022562 A8 BR112014022562 A8 BR 112014022562A8
- Authority
- BR
- Brazil
- Prior art keywords
- immunotherapy
- rna
- systemic administration
- present
- rna formulation
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 238000007910 systemic administration Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
FORMULAÇÃO DE RNA PARA IMUNOTERAPIA. A presente invenção está no campo da imunoterapia, em particular, a imunoterapia tumoral. A presente invenção proporciona formulações farmacêuticas para a distribuição de RNA para as células apresentadoras de antígenos, tais como células dendrítcas (DCs) no baço, após a administração sistêmica. Em particular, as formulações aqui descritas permitem induzir uma resposta imunológica após a administração sistêmica de RNA que codifica antígeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2012/001319 WO2013143555A1 (en) | 2012-03-26 | 2012-03-26 | Rna formulation for immunotherapy |
PCT/EP2013/000902 WO2013143683A1 (en) | 2012-03-26 | 2013-03-25 | Rna formulation for immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014022562A2 BR112014022562A2 (pt) | 2017-08-22 |
BR112014022562A8 true BR112014022562A8 (pt) | 2022-10-11 |
Family
ID=48044720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014022562A BR112014022562A8 (pt) | 2012-03-26 | 2013-03-25 | Formulação de rna para imunoterapia |
Country Status (19)
Country | Link |
---|---|
US (3) | US10485884B2 (pt) |
JP (4) | JP6279545B2 (pt) |
CN (2) | CN109331176B (pt) |
AU (3) | AU2013242512B2 (pt) |
BR (1) | BR112014022562A8 (pt) |
CA (2) | CA2864253C (pt) |
DK (1) | DK2830593T3 (pt) |
ES (2) | ES2719480T3 (pt) |
HK (1) | HK1202060A1 (pt) |
HR (1) | HRP20201578T1 (pt) |
HU (2) | HUE052485T2 (pt) |
LT (2) | LT2830593T (pt) |
MX (3) | MX2014011466A (pt) |
NZ (1) | NZ628328A (pt) |
PT (2) | PT3427723T (pt) |
RS (1) | RS61002B1 (pt) |
SI (1) | SI3427723T1 (pt) |
TR (1) | TR201904758T4 (pt) |
WO (2) | WO2013143555A1 (pt) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
AU2012267578B2 (en) | 2011-06-08 | 2017-04-20 | Translate Bio, Inc. | Cleavable lipids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
DE21212055T1 (de) | 2011-12-07 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Biologisch abbaubare lipide zur freisetzung von wirkstoffen |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
WO2013151667A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
KR102134056B1 (ko) | 2013-02-22 | 2020-07-15 | 큐어백 아게 | Pd―1 경로의 억제 및 백신접종의 조합물 |
EP3578200A1 (en) | 2013-02-22 | 2019-12-11 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
MX2016011686A (es) | 2014-03-09 | 2016-11-07 | Univ Pennsylvania | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
SI3134131T1 (sl) * | 2014-04-23 | 2022-04-29 | Modernatx, Inc. | Cepiva na osnovi nukleinskih kislin |
HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
EP3261605B2 (en) | 2015-02-26 | 2022-04-20 | SiO2 Medical Products, Inc. | Cycloolefin polymer container with a scratch resistant and anti-static coating |
WO2016155809A1 (en) * | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
ES2753259T3 (es) | 2015-04-22 | 2020-04-07 | Curevac Ag | Composición que contiene ARN para el tratamiento de enfermedades tumorales |
US20180110877A1 (en) | 2015-04-27 | 2018-04-26 | The Trustees Of The University Of Pennsylvania | DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE |
WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
US11090332B2 (en) * | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
IL283545B2 (en) | 2015-06-29 | 2023-09-01 | Acuitas Therapeutics Inc | Lipids and nanoparticulate lipid formulations for delivery of nucleic acids |
WO2017015457A1 (en) * | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
US10676735B2 (en) | 2015-07-22 | 2020-06-09 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
IL288662B2 (en) | 2015-08-25 | 2023-09-01 | Univ Duke | Preparations and methods for improving specificity in genomic engineering using RNA-guided endonucleases |
EP3736261B1 (en) | 2015-09-17 | 2023-10-11 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3362571A4 (en) | 2015-10-13 | 2019-07-10 | Duke University | GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS |
BR112018008090A2 (pt) * | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
CN108430456B (zh) * | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
EP3365007A4 (en) * | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINE AGAINST BROAD SPECTRUM INFLUENZA VIRUS |
PT3368507T (pt) | 2015-10-28 | 2023-02-07 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
KR20180118105A (ko) * | 2015-12-04 | 2018-10-30 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 면역치료를 위한 slc45a2 펩티드 |
MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
ES2913626T3 (es) | 2015-12-22 | 2022-06-03 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
EP3442590A2 (en) | 2016-04-13 | 2019-02-20 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
PL3458083T3 (pl) | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
EP3458034A4 (en) | 2016-05-18 | 2020-01-01 | ModernaTX, Inc. | POLYNUCLEOTIDS FOR THE CODING OF RELAXIN |
KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
PL3596041T3 (pl) | 2017-03-15 | 2023-03-06 | Modernatx, Inc. | Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych |
ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
JP7264867B2 (ja) * | 2017-03-31 | 2023-04-25 | アッカニス・バイオテック・エフ・アンド・イー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | 非メラノーマ皮膚癌(nmsc)の予防および治療 |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
WO2018200892A1 (en) | 2017-04-27 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS |
EP3615510B1 (en) | 2017-04-28 | 2024-03-27 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
US11633365B2 (en) | 2017-08-04 | 2023-04-25 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
US20200277627A1 (en) | 2017-09-13 | 2020-09-03 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
CA3074919A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
JP2021500324A (ja) * | 2017-10-20 | 2021-01-07 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh | 治療に適するリポソームrna製剤の調製および保管 |
WO2019154985A1 (en) | 2018-02-12 | 2019-08-15 | Biontech Rna Pharmaceuticals Gmbh | Treatment using cytokine encoding rna |
CN112119084A (zh) | 2018-03-15 | 2020-12-22 | 生物技术Rna制药有限公司 | 5′-帽三核苷酸或更高级寡核苷酸化合物及其在使rna稳定、表达蛋白质和治疗中的用途 |
WO2020020444A1 (en) | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
EP3827014A1 (en) | 2018-07-24 | 2021-06-02 | BioNTech RNA Pharmaceuticals GmbH | Il2 agonists |
WO2020037102A1 (en) * | 2018-08-15 | 2020-02-20 | University Of Florida Research Foundation, Inc. | Methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
CA3108229A1 (en) * | 2018-09-18 | 2020-03-26 | Universiteit Gent | Therapeutic nanoparticles and methods of use thereof |
US20220062439A1 (en) | 2019-01-10 | 2022-03-03 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
BR112021013654A2 (pt) | 2019-01-11 | 2021-09-14 | Acuitas Therapeutics, Inc. | Lipídeos para liberação de nanopartículas lipídicas de agentes ativos |
WO2020150152A1 (en) | 2019-01-14 | 2020-07-23 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
EP3920960B1 (en) | 2019-02-08 | 2024-04-17 | Biontech Cell & Gene Therapies Gmbh | Treatment involving car-engineered t cells and cytokines |
SG11202108339TA (en) | 2019-02-08 | 2021-08-30 | Biontech Cell & Gene Therapies Gmbh | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers |
AU2020233995A1 (en) | 2019-03-12 | 2021-09-23 | BioNTech SE | Therapeutic RNA for prostate cancer |
CU20210078A7 (es) | 2019-03-18 | 2022-04-07 | Biontech Cell & Gene Therapies Gmbh | Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activación específica de células efectoras inmunitarias |
WO2020200481A1 (en) | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
WO2020200472A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Preparation and storage of liposomal rna formulations suitable for therapy |
EP3972632A1 (en) | 2019-05-20 | 2022-03-30 | BioNTech SE | Therapeutic rna for ovarian cancer |
TW202115105A (zh) | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
CN114728887A (zh) | 2019-09-19 | 2022-07-08 | 摩登纳特斯有限公司 | 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物 |
US20220409708A1 (en) * | 2019-11-01 | 2022-12-29 | Korea Advanced Institute Of Science And Technology | Small lipid nanoparticles, and cancer vaccine including same |
EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
WO2021129945A1 (en) | 2019-12-27 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins) |
JP2023512654A (ja) | 2020-01-31 | 2023-03-28 | ジェネンテック, インコーポレイテッド | Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法 |
WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
EP4121101A1 (en) | 2020-03-16 | 2023-01-25 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
WO2021197589A1 (en) | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
EP4133071A2 (en) * | 2020-04-09 | 2023-02-15 | Verve Therapeutics, Inc. | Base editing of angptl3 and methods of using same for treatment of disease |
WO2021205077A1 (en) | 2020-04-09 | 2021-10-14 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
US20230265454A1 (en) | 2020-06-04 | 2023-08-24 | BioNTech SE | RNA Replicon for Versatile and Efficient Gene Expression |
CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
CN116096702A (zh) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | 用于脂质纳米颗粒的阳离子脂质 |
US20220122690A1 (en) | 2020-07-17 | 2022-04-21 | Genentech, Inc. | Attention-based neural network to predict peptide binding, presentation, and immunogenicity |
IL300997A (en) | 2020-09-08 | 2023-04-01 | Genentech Inc | Systems and methods for the production of pharmaceutical preparations using peristaltic pumps and restraints |
MX2023005386A (es) | 2020-11-11 | 2023-05-23 | BioNTech SE | Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina. |
EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
IT202100003470A1 (it) | 2021-02-16 | 2022-08-16 | Fond Toscana Life Sciences | Vaccines against sars-cov-2 |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
JP2024511067A (ja) | 2021-03-19 | 2024-03-12 | トレインド セラピューティクス ディスカバリー,インコーポレーテッド | 訓練された免疫を調節するための化合物およびその使用方法 |
KR20240009419A (ko) | 2021-04-20 | 2024-01-22 | 비온테크 에스이 | 바이러스 백신 |
IL308196A (en) | 2021-05-04 | 2024-01-01 | BioNTech SE | Technologies for the early detection of interesting variants |
IL309021A (en) | 2021-06-08 | 2024-01-01 | Biontech Cell & Gene Therapies Gmbh | Agents and methods for activation and targeting of immune effector cells |
IL309952A (en) | 2021-07-29 | 2024-03-01 | BioNTech SE | Compositions and methods for treating melanoma |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
TW202333803A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(一) |
WO2023061550A1 (en) | 2021-10-11 | 2023-04-20 | BioNTech SE | Therapeutic rna for lung cancer |
WO2023064612A2 (en) | 2021-10-15 | 2023-04-20 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
CA3234396A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
CA3234214A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
WO2023066923A1 (en) | 2021-10-19 | 2023-04-27 | Rahman Nafis | Male contraception |
WO2023066496A1 (en) | 2021-10-21 | 2023-04-27 | BioNTech SE | Coronavirus vaccine |
WO2023067193A2 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions for administration of different doses of rna |
WO2023073190A1 (en) | 2021-10-28 | 2023-05-04 | BioNTech SE | Rna constructs and uses thereof |
FR3129833A1 (fr) | 2021-12-03 | 2023-06-09 | Universite Claude Bernard Lyon 1 | Nanoparticules pour la liberation d’acides nucleiques |
WO2023105005A1 (en) | 2021-12-09 | 2023-06-15 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023148277A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery of nucleic acids to cells |
WO2023148276A1 (en) | 2022-02-02 | 2023-08-10 | BioNTech SE | Agents and methods for targeted delivery to cells |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
US11932693B2 (en) | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2023237726A1 (en) | 2022-06-10 | 2023-12-14 | Pantarhei Oncology B.V. | An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
CN115300641A (zh) * | 2022-08-01 | 2022-11-08 | 深圳市人民医院 | 一种靶向树突状细胞促进抗原溶酶体逃逸激活免疫系统的抗原递送载体其制备方法与应用 |
WO2024028445A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024075022A2 (en) | 2022-10-04 | 2024-04-11 | BioNTech SE | Rna constructs and uses thereof |
WO2024107754A1 (en) | 2022-11-15 | 2024-05-23 | Genentech, Inc. | Selection of diverse candidate peptides for peptide therapeutics |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
JPH11504631A (ja) * | 1995-04-25 | 1999-04-27 | バイカル インコーポレイテッド | Dna/脂質複合体の単一バイアル製剤 |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
CA2227065A1 (en) | 1995-07-21 | 1997-02-06 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
ES2205209T3 (es) | 1996-04-26 | 2004-05-01 | Rijksuniversiteit Te Leiden | Procedimientos de seleccion y de produccion de epitopos peptidicos de linfocitos t y vacunas que contienen los indicados epitopos seleccionados. |
WO1998010748A1 (en) | 1996-09-13 | 1998-03-19 | The School Of Pharmacy | Liposomes |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
BR9813981A (pt) | 1997-11-06 | 2000-09-26 | Roche Diagnostics Gmbh | Antìgenos de tumor especìficos, métodos para a sua produção e seu uso imunização de diagnóstico |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
CA2345440A1 (en) | 1998-10-05 | 2000-04-13 | Charles A. Nicolette | Genes differentially expressed in cancer cells to design cancer vaccines |
AU4700100A (en) | 1999-05-06 | 2000-11-21 | Wake Forest University | Compositions and methods for identifying antigens which elicit an immune response |
EP1261704B1 (en) | 1999-11-30 | 2009-07-01 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
AU780064B2 (en) | 1999-12-28 | 2005-02-24 | Epimmune, Inc. | Optimized minigenes and peptides encoded thereby |
US20040052763A1 (en) | 2000-06-07 | 2004-03-18 | Mond James J. | Immunostimulatory RNA/DNA hybrid molecules |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
ES2356934T3 (es) | 2001-06-05 | 2011-04-14 | Curevac Gmbh | ARNm ESTABILIZADO CON UN CONTENIDO DE G/C AUMENTADO QUE CODIFICA PARA UN ANTÍGENO VIRAL. |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
ATE519115T1 (de) | 2002-06-13 | 2011-08-15 | Merck Patent Gmbh | Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
ES2574231T3 (es) | 2003-10-15 | 2016-06-16 | Syncore Biotechnology Co., Ltd | Uso de liposomas catiónicos que comprenden paclitaxel |
JP4931593B2 (ja) | 2003-10-24 | 2012-05-16 | イミュネイド ピーティーワイ リミテッド | 治療の方法 |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
MX2007008010A (es) | 2004-12-29 | 2007-09-07 | Mannkind Corp | Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta. |
PT2161336E (pt) | 2005-05-09 | 2013-10-03 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿ |
KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
EP2578685B1 (en) | 2005-08-23 | 2019-04-17 | The Trustees Of The University Of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
JP2009532664A (ja) | 2006-02-27 | 2009-09-10 | アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ | 癌の治療のためのノボペプチドの同定および使用 |
CA2663521A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
CA2675378A1 (en) | 2007-01-29 | 2008-08-07 | Medipol Sa | Chitosan-based colloidal particles for rna delivery |
EP1955695A1 (en) * | 2007-02-06 | 2008-08-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nanocapsules of lipophilic complexes of nucleic acids |
US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
SG189692A1 (en) | 2008-03-24 | 2013-05-31 | 4Sc Discovery Gmbh | Novel substituted imidazoquinolines |
ES2712505T3 (es) | 2008-04-17 | 2019-05-13 | Pds Biotechnology Corp | Estimulación de una respuesta inmunitaria por enantiómeros de lípidos catiónicos |
PL215513B1 (pl) * | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
TW201004658A (en) | 2008-07-31 | 2010-02-01 | Enzon Pharmaceuticals Inc | Nanoparticle compositions for nucleic acids delivery system |
JP5382682B2 (ja) * | 2008-09-01 | 2014-01-08 | 国立大学法人 長崎大学 | 薬物送達複合体 |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
DE102008061522A1 (de) * | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
WO2011005799A2 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
US20120195936A1 (en) | 2009-07-31 | 2012-08-02 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
EP3391877A1 (en) | 2010-04-08 | 2018-10-24 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
EP3023788B1 (en) | 2010-05-14 | 2020-02-12 | The General Hospital Corporation | Compositions of tumor specific neoantigens for use in treating tumours |
EP2590626B1 (en) * | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
CN102133404B (zh) * | 2011-03-23 | 2013-01-16 | 成都诺恩生物科技有限公司 | 一种肿瘤靶向治疗药物载体、其制备方法及其应用 |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
JP2014520806A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Rna分子の送達のための有用なn:p比を有するリポソーム |
EP3424495A1 (en) * | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US20150030576A1 (en) | 2012-01-10 | 2015-01-29 | Moderna Therapeutics, Inc. | Methods and compositions for targeting agents into and across the blood-brain barrier |
WO2013113325A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013124701A2 (en) | 2012-02-20 | 2013-08-29 | Universita' Degli Studi Di Milano | New homo- and heterodimeric smac mimetic compounds as apoptosis inducers |
EP2830593B1 (en) | 2012-03-26 | 2019-02-27 | BioNTech RNA Pharmaceuticals GmbH | Rna formulation for immunotherapy |
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
WO2013151667A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
EP2872653B1 (en) | 2012-07-12 | 2019-03-13 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
JP6510416B2 (ja) | 2012-11-01 | 2019-05-08 | ファクター バイオサイエンス インコーポレイテッド | 細胞中でタンパク質を発現するための方法および生成物 |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
US10138507B2 (en) | 2013-03-15 | 2018-11-27 | Modernatx, Inc. | Manufacturing methods for production of RNA transcripts |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
EP2983702A2 (en) | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3043826A4 (en) | 2013-09-13 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
EP3049065A1 (en) | 2013-09-26 | 2016-08-03 | BioNTech AG | Particles comprising a shell with rna |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
US20160264614A1 (en) | 2013-10-02 | 2016-09-15 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
EP3076994A4 (en) | 2013-12-06 | 2017-06-07 | Modernatx, Inc. | Targeted adaptive vaccines |
US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
AU2014381849A1 (en) | 2014-02-05 | 2016-08-25 | Biontech Ag | A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
SI3134131T1 (sl) | 2014-04-23 | 2022-04-29 | Modernatx, Inc. | Cepiva na osnovi nukleinskih kislin |
WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
EP3230458B1 (en) | 2014-12-12 | 2020-02-19 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
BR112017009835A2 (pt) | 2014-12-30 | 2017-12-26 | Curevac Ag | moléculas de ácido nucleico artificiais |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
-
2012
- 2012-03-26 WO PCT/EP2012/001319 patent/WO2013143555A1/en active Application Filing
-
2013
- 2013-03-25 RS RS20201186A patent/RS61002B1/sr unknown
- 2013-03-25 NZ NZ628328A patent/NZ628328A/en unknown
- 2013-03-25 CA CA2864253A patent/CA2864253C/en active Active
- 2013-03-25 SI SI201331795T patent/SI3427723T1/sl unknown
- 2013-03-25 CN CN201811246680.XA patent/CN109331176B/zh active Active
- 2013-03-25 CA CA3088428A patent/CA3088428C/en active Active
- 2013-03-25 LT LTEP13713356.7T patent/LT2830593T/lt unknown
- 2013-03-25 BR BR112014022562A patent/BR112014022562A8/pt not_active Application Discontinuation
- 2013-03-25 HU HUE18171522A patent/HUE052485T2/hu unknown
- 2013-03-25 PT PT181715228T patent/PT3427723T/pt unknown
- 2013-03-25 CN CN201380016262.0A patent/CN104302276A/zh active Pending
- 2013-03-25 WO PCT/EP2013/000902 patent/WO2013143683A1/en active Application Filing
- 2013-03-25 LT LTEP18171522.8T patent/LT3427723T/lt unknown
- 2013-03-25 DK DK13713356.7T patent/DK2830593T3/en active
- 2013-03-25 AU AU2013242512A patent/AU2013242512B2/en active Active
- 2013-03-25 US US14/388,192 patent/US10485884B2/en active Active
- 2013-03-25 HU HUE13713356 patent/HUE044594T2/hu unknown
- 2013-03-25 MX MX2014011466A patent/MX2014011466A/es active IP Right Grant
- 2013-03-25 ES ES13713356T patent/ES2719480T3/es active Active
- 2013-03-25 PT PT13713356T patent/PT2830593T/pt unknown
- 2013-03-25 JP JP2015502136A patent/JP6279545B2/ja active Active
- 2013-03-25 ES ES18171522T patent/ES2823239T3/es active Active
- 2013-03-25 TR TR2019/04758T patent/TR201904758T4/tr unknown
-
2014
- 2014-09-24 MX MX2020011781A patent/MX2020011781A/es unknown
- 2014-09-24 MX MX2020011696A patent/MX2020011696A/es unknown
-
2015
- 2015-03-13 HK HK15102573.4A patent/HK1202060A1/xx unknown
-
2017
- 2017-11-14 JP JP2017219079A patent/JP6596478B2/ja active Active
- 2017-12-18 AU AU2017279565A patent/AU2017279565B2/en active Active
-
2018
- 2018-11-28 JP JP2018222175A patent/JP6832904B2/ja active Active
-
2019
- 2019-09-23 US US16/578,601 patent/US11559587B2/en active Active
-
2020
- 2020-03-26 AU AU2020202152A patent/AU2020202152B2/en active Active
- 2020-04-06 JP JP2020068394A patent/JP7096282B2/ja active Active
- 2020-10-05 HR HRP20201578TT patent/HRP20201578T1/hr unknown
-
2022
- 2022-11-30 US US18/071,705 patent/US20230226217A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014022562A8 (pt) | Formulação de rna para imunoterapia | |
CY1123649T1 (el) | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη | |
MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
CY1121232T1 (el) | Τριαλκυλο κατιονικα λιπιδια και μεθοδοι χρησης αυτων | |
CY1124499T1 (el) | Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα | |
CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
CL2017001819A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer | |
CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
CU20160060A7 (es) | Péptidos, ácidos nucleicos y células, útiles en la inmunoterapia personalizada contra diversos tumores cerebrales y neuronales | |
CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
MX351453B (es) | Composiciones de liberacion sostenida a base de lipidos anfipaticos. | |
PE20142406A1 (es) | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna | |
SG11201602943PA (en) | Lipid formulations for delivery of messenger rna | |
IN2014MN02069A (pt) | ||
MX363226B (es) | Formulaciones de anticuerpos. | |
TR201908003T4 (tr) | TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları. | |
MX349004B (es) | Nuevos compuestos. | |
CY1123453T1 (el) | Σκευασμα rna για ανοσοθεραπεια | |
MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
TN2014000518A1 (en) | Reassortant btv and ahsv vaccines | |
TN2013000313A1 (en) | Isoxazolidine derivatives | |
MX2013013243A (es) | Medios y metodos para activar la inmunoterapia celular del cancer utilizando celulas cancerosas destruidas mediante presion hidrostatica y celulas dendriticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER JOHANNES GU |
|
B25A | Requested transfer of rights approved |
Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE) , TRON - TR |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE) ; TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) |
|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; BIONTECH SE (DE) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |